Upstream Bio Inc (UPB) FinancialsUPBFinancialUpstream Bio Inc

Evaluating the bottom line, Upstream Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5480.98%, while the net margin is -5136.09%. These profitability ratios, combined with a Return on Equity (ROE) of -46.05%, provide a clear picture of how effectively UPB converts its operational activities into shareholder value.

In the context of the broader market, UPB competes directly with industry leaders such as IPSC and ZNTL. With a market capitalization of $366.42M, it holds a significant position in the sector. When comparing efficiency, UPB's gross margin of N/A stands against IPSC's N/A and ZNTL's N/A. Such benchmarking helps identify whether Upstream Bio, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue with Q1 2026 revenue at $1.03 million, but net losses have been substantial, reaching $40.6 million in Q1 and $39.7 million in Q2 2026. Gross margin remains high at 100% for recent quarters, but net income is heavily negative.